期刊文献+

糖尿病肾病差异蛋白质组分析 被引量:3

Proteome analysis of diabetic nephropathy urinary
原文传递
导出
摘要 目的 :利用弱阳离子磁珠纯化(magnetic beads based weak cation exchange chromatography,MB-WCX)系统结合基质辅助激光解析电离-飞行时间质谱(matrix-assisted laser desorption/ionization time-of-flight mass spectrometry,MALDI-TOF-MS)的方法获取糖尿病肾病(diabetic nephropathy,DN)的尿小分子差异多肽谱。方法:按Mogensen标准,根据3 d平均微量白蛋白尿排泄率,将68例2型糖尿病患者分组,其中正常蛋白尿(DM1)组24例,微量白蛋白(DM2)组22例,大量蛋白(DM3)组22例;健康对照(C)组20例。DM1及DM2组肾小球率过滤(glomerular filtration rate,GFR)均>90 ml/(min.1.73 m2),DM3组GFR为60~89 ml/(min.1.73 m2)。采用MB-WCX试剂盒富集尿多肽,再经MALDI-TOF-MS技术,采集尿液多肽谱,应用ClinProtTM软件进行生物学比较分析。结果:质荷比<12 000时,DM1组与C组相比,有15个蛋白质峰差异有统计学意义(P<0.01)。DM2组与C组相比,有1个蛋白质峰差异有统计学意义(P=0.029 8)。DM3组与C组相比,有10个蛋白质峰差异有统计学意义(P<0.01)。结论:MB-WCX系统联合MALDI-TOF-MS蛋白质检测技术,能够获得健康人及DN患者尿液小分子多肽谱,为进一步从中寻找早期筛查的标志物提供基础。 Objective:To detect urinary polypeptide patterns in stages of the type 2 diabetic nephropathy (DN) in order to screen and find out the potential biomarkers. Methods:A total of 68 urine samples from type 2 diabetic patients with normoalbuminuria (DMI,n = 24),microalbuminuria (DM2,n = 22)and maeroalbuminuria (DM3,rt = 22),and healthy controls (C,n = 20) were condensed by magnetic beads based weak cation exchange chromatography (MB-WCX),and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). ClinProtTM software was used to profile and screen the polypeptide patterns in urine of the patients. Results:When the relative molecular mass 〈 12 000, there were significant differences in 15 protein peaks between group DM1 and group C(P 〈 0.01 ). There was one protein peak of significantly low expression in the group DM2,when compared to group C (P = 0.029 8). And there were significant differences in 10 protein peaks between group DM3 and group C (P 〈 0.01 ). Conclusion: MB-WCX coupled to MALDI-TOF-MS is a fast, convenient and high throughput analyzing method capable of screening some relatively specific and potential biomarkers from the urine of DN with different stages.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2012年第7期1033-1037,共5页 Journal of Nanjing Medical University(Natural Sciences)
关键词 磁珠分离 基质辅助激光解吸电离-飞行时间质谱 糖尿病肾病 尿液 多肽 magnetic beads separation matrix-assisted laser desorption/ionization time-of-flight mass spectrometry diabeticnephropathy urine polypeptide
  • 相关文献

参考文献1

二级参考文献15

  • 1Y.-L. He,R. Sabo,J. Campestrini,Y. Wang,M. Ligueros-Saylan,K. C. Lasseter,S. C. Dilzer,D. Howard,W. P. Dole.The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin[J].European Journal of Clinical Pharmacology.2007(7)
  • 2V. Fonseca,A. Schweizer,D. Albrecht,M. A. Baron,I. Chang,S. Dejager.Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes[J].Diabetologia.2007(6)
  • 3N. Matikainen,S. M?ntt?ri,A. Schweizer,A. Ulvestad,D. Mills,B. E. Dunning,J. E. Foley,M.-R. Taskinen.Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes[J].Diabetologia.2006(9)
  • 4Catherine A. Abbott,Geoffrey W. McCaughan,Elizabeth Baker,Grant R. Sutherland.Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene[J].Immunogenetics.1994(5)
  • 5André Wettergren MD,Birgit Schjoldager MD,Poul Erik Mortensen MD,John Myhre MD,John Christiansen MD,Dr. Jens Juul Holst MD.Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man[J].Digestive Diseases and Sciences.1993(4)
  • 6Ahrén B,Simonsson E,Larsson H,Landin-Olsson M,Torgeirsson H,Jansson PA.Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes[].Diabetes Care.2002
  • 7Pratley RE,,Jauffret-Kamel S,Galbreath E,Holmes D.Twelveweek monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes[].Hormone and Metabolic Research.2006
  • 8Raz I,Chen Y,Wu M,Hussain S,Kaufman KD,Amatruda JM.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes[].Current Medical Research and Opinion.2008
  • 9Lauster CD,McKaveney TP,Muench SV.Vildagliptin: a novel oral therapy for type 2 diabetes mellitus[].American Journal of Health System Pharmacy.2007
  • 10Choy M,Lam S.Sitagliptin: a novel drug for the treatment of type 2 diabetes[].Cardiology Review.2007

共引文献8

同被引文献28

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部